WHO confirmed a Phase III study conducted in the U.S. and Mexico during a period in which multiple variants (Alpha, Beta, and Delta) were in circulation found the Novavax vaccine efficacy against mild, moderate, or severe COVID-19 was 90%.
The company is also developing a COVID-19-Influenza Combination (CIC), with CEO Stanley C. Erck saying, “We believe that like influenza, COVID-19 will also be seasonal moving forward, and that there is room in the market for new alternatives to provide better protection against the impact of influenza, particularly in older adults, and to explore the potential to combine this with protection from COVID.”
In a Phase 3 study conducted in the USA and Mexico during a period in which multiple variants (Alpha, Beta and Delta) were in circulation, vaccine efficacy against mild, moderate, or severe COVID-19 was 90%.
In view of these findings, WHO recommends the use of Novavax (NVX-CoV2373) vaccine according to the WHO Prioritization Roadmap, even if currently recognized Variants of Concern (VOC) are present in the country. If new VOCs emerge for which vaccine performance is compromised, these recommendations will be updated accordingly. There are insufficient data still for Omicron.
New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants
HyPerforma DynaDrive 一次性生物反应器